Am J Obstet Gynecol:唾液皮质醇表达与分娩生理、心理应激反应:前瞻性研究

2019-09-30 anesthGH “罂粟花”微信号

分娩被认为是一个应激性事件,但尚无研究报道通过分娩时及产后的皮质醇表达水平来监测分娩应激过程。本研究旨在阐明分娩过程中通过唾液皮质醇浓度和压力调查问卷进行测量的生理和心理应激模式,以及它们与产科和新生儿结局的关系。

背景与目的

分娩被认为是一个应激性事件,但尚无研究报道通过分娩时及产后的皮质醇表达水平来监测分娩应激过程。本研究旨在阐明分娩过程中通过唾液皮质醇浓度和压力调查问卷进行测量的生理和心理应激模式,以及它们与产科和新生儿结局的关系。

方  法

本项前瞻性观察性研究共收集了来自同一所高等学术中心的167名低风险、单胎、足月妊娠的孕妇。分别于分娩潜伏期、活跃期、宫颈完全扩张期以及分娩后2min、2h、24h,采用唾液皮质醇测量值和情绪压力问卷(压力量表0~10)对生理应激进行评估。测定脐带血皮质醇和pH值。评估分娩方式、阵痛与分娩期间并发症和新生儿早期结局。

结 果

唾液皮质醇浓度由潜伏期至活跃期逐渐升高。分娩后2min内观察到了上升的最大值(从平均值1.06 μg/dl上升至1.67 μg/dl:升高了57%)。分娩后2h内,皮质醇浓度逐渐下降,并在分娩24h后达到非妊娠水平(0.16 μg/dl)。分娩期间和产后2h内皮质醇浓度高于非妊娠妇女平均浓度(0.5 μg/dl)。与非硬膜外麻醉的产妇相比,硬膜外麻醉的产妇在宫颈开全时(p=0.026)和产后2h(p=0.016)的皮质醇浓度较低。心理应激在潜伏期和宫颈完全扩张期达到峰值(平均值分别为4.56、4.29),产后即刻出现最大降幅(从4.29下降至2.04,下降了52%)。胎头吸引术分娩组脐带血皮质醇水平高于自然阴道分娩组(17±2 vs. 11±3.8,p=0.03)。

结 论

本项研究揭示了低风险孕妇分娩时皮质醇浓度的变化过程,其中最大上升出现在产后数分钟内。主观应激水平在分娩过程中逐渐下降。唾液皮质醇浓度变化反映了分娩过程中的应激状况,可作为参考以评估复杂妊娠和皮质醇在分娩过程中的作用。

原始出处:

Miller N, Asali AA, Agassi-Zaitler M, et al. Physiological and psychological stress responses to labor and delivery as expressed by salivary cortisol: a prospective study.[J]. Am J Obstet Gynecol 2019. DOI:10.1016/j.ajog.2019.06.045

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044111, encodeId=fdc82044111d2, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 12 16:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774855, encodeId=69f01e74855fd, content=<a href='/topic/show?id=fb905115046' target=_blank style='color:#2F92EE;'>#心理应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51150, encryptionId=fb905115046, topicName=心理应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bf538680838, createdName=nian.wang1995, createdTime=Wed Jun 10 17:15:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006466, encodeId=93ae2006466a0, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Wed Feb 26 00:15:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653852, encodeId=387e1653852e9, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Sun Jun 28 07:15:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046173, encodeId=455720461e3b4, content=<a href='/topic/show?id=4dbb4003e19' target=_blank style='color:#2F92EE;'>#唾液皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40037, encryptionId=4dbb4003e19, topicName=唾液皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 31 03:15:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914468, encodeId=4a1a1914468b8, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Dec 28 22:15:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011416, encodeId=97132011416b0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Jul 22 13:15:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275189, encodeId=1fff12e51895f, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277820, encodeId=efc712e7820ae, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445299, encodeId=01021445299f9, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044111, encodeId=fdc82044111d2, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 12 16:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774855, encodeId=69f01e74855fd, content=<a href='/topic/show?id=fb905115046' target=_blank style='color:#2F92EE;'>#心理应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51150, encryptionId=fb905115046, topicName=心理应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bf538680838, createdName=nian.wang1995, createdTime=Wed Jun 10 17:15:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006466, encodeId=93ae2006466a0, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Wed Feb 26 00:15:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653852, encodeId=387e1653852e9, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Sun Jun 28 07:15:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046173, encodeId=455720461e3b4, content=<a href='/topic/show?id=4dbb4003e19' target=_blank style='color:#2F92EE;'>#唾液皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40037, encryptionId=4dbb4003e19, topicName=唾液皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 31 03:15:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914468, encodeId=4a1a1914468b8, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Dec 28 22:15:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011416, encodeId=97132011416b0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Jul 22 13:15:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275189, encodeId=1fff12e51895f, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277820, encodeId=efc712e7820ae, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445299, encodeId=01021445299f9, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044111, encodeId=fdc82044111d2, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 12 16:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774855, encodeId=69f01e74855fd, content=<a href='/topic/show?id=fb905115046' target=_blank style='color:#2F92EE;'>#心理应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51150, encryptionId=fb905115046, topicName=心理应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bf538680838, createdName=nian.wang1995, createdTime=Wed Jun 10 17:15:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006466, encodeId=93ae2006466a0, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Wed Feb 26 00:15:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653852, encodeId=387e1653852e9, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Sun Jun 28 07:15:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046173, encodeId=455720461e3b4, content=<a href='/topic/show?id=4dbb4003e19' target=_blank style='color:#2F92EE;'>#唾液皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40037, encryptionId=4dbb4003e19, topicName=唾液皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 31 03:15:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914468, encodeId=4a1a1914468b8, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Dec 28 22:15:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011416, encodeId=97132011416b0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Jul 22 13:15:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275189, encodeId=1fff12e51895f, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277820, encodeId=efc712e7820ae, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445299, encodeId=01021445299f9, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2044111, encodeId=fdc82044111d2, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 12 16:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774855, encodeId=69f01e74855fd, content=<a href='/topic/show?id=fb905115046' target=_blank style='color:#2F92EE;'>#心理应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51150, encryptionId=fb905115046, topicName=心理应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bf538680838, createdName=nian.wang1995, createdTime=Wed Jun 10 17:15:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006466, encodeId=93ae2006466a0, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Wed Feb 26 00:15:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653852, encodeId=387e1653852e9, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Sun Jun 28 07:15:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046173, encodeId=455720461e3b4, content=<a href='/topic/show?id=4dbb4003e19' target=_blank style='color:#2F92EE;'>#唾液皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40037, encryptionId=4dbb4003e19, topicName=唾液皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 31 03:15:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914468, encodeId=4a1a1914468b8, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Dec 28 22:15:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011416, encodeId=97132011416b0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Jul 22 13:15:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275189, encodeId=1fff12e51895f, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277820, encodeId=efc712e7820ae, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445299, encodeId=01021445299f9, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2044111, encodeId=fdc82044111d2, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 12 16:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774855, encodeId=69f01e74855fd, content=<a href='/topic/show?id=fb905115046' target=_blank style='color:#2F92EE;'>#心理应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51150, encryptionId=fb905115046, topicName=心理应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bf538680838, createdName=nian.wang1995, createdTime=Wed Jun 10 17:15:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006466, encodeId=93ae2006466a0, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Wed Feb 26 00:15:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653852, encodeId=387e1653852e9, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Sun Jun 28 07:15:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046173, encodeId=455720461e3b4, content=<a href='/topic/show?id=4dbb4003e19' target=_blank style='color:#2F92EE;'>#唾液皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40037, encryptionId=4dbb4003e19, topicName=唾液皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 31 03:15:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914468, encodeId=4a1a1914468b8, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Dec 28 22:15:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011416, encodeId=97132011416b0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Jul 22 13:15:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275189, encodeId=1fff12e51895f, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277820, encodeId=efc712e7820ae, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445299, encodeId=01021445299f9, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2044111, encodeId=fdc82044111d2, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 12 16:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774855, encodeId=69f01e74855fd, content=<a href='/topic/show?id=fb905115046' target=_blank style='color:#2F92EE;'>#心理应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51150, encryptionId=fb905115046, topicName=心理应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bf538680838, createdName=nian.wang1995, createdTime=Wed Jun 10 17:15:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006466, encodeId=93ae2006466a0, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Wed Feb 26 00:15:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653852, encodeId=387e1653852e9, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Sun Jun 28 07:15:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046173, encodeId=455720461e3b4, content=<a href='/topic/show?id=4dbb4003e19' target=_blank style='color:#2F92EE;'>#唾液皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40037, encryptionId=4dbb4003e19, topicName=唾液皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 31 03:15:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914468, encodeId=4a1a1914468b8, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Dec 28 22:15:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011416, encodeId=97132011416b0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Jul 22 13:15:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275189, encodeId=1fff12e51895f, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277820, encodeId=efc712e7820ae, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445299, encodeId=01021445299f9, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2044111, encodeId=fdc82044111d2, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 12 16:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774855, encodeId=69f01e74855fd, content=<a href='/topic/show?id=fb905115046' target=_blank style='color:#2F92EE;'>#心理应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51150, encryptionId=fb905115046, topicName=心理应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bf538680838, createdName=nian.wang1995, createdTime=Wed Jun 10 17:15:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006466, encodeId=93ae2006466a0, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Wed Feb 26 00:15:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653852, encodeId=387e1653852e9, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Sun Jun 28 07:15:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046173, encodeId=455720461e3b4, content=<a href='/topic/show?id=4dbb4003e19' target=_blank style='color:#2F92EE;'>#唾液皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40037, encryptionId=4dbb4003e19, topicName=唾液皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 31 03:15:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914468, encodeId=4a1a1914468b8, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Dec 28 22:15:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011416, encodeId=97132011416b0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Jul 22 13:15:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275189, encodeId=1fff12e51895f, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277820, encodeId=efc712e7820ae, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445299, encodeId=01021445299f9, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=)]
    2020-07-22 yhy100200
  8. [GetPortalCommentsPageByObjectIdResponse(id=2044111, encodeId=fdc82044111d2, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 12 16:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774855, encodeId=69f01e74855fd, content=<a href='/topic/show?id=fb905115046' target=_blank style='color:#2F92EE;'>#心理应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51150, encryptionId=fb905115046, topicName=心理应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bf538680838, createdName=nian.wang1995, createdTime=Wed Jun 10 17:15:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006466, encodeId=93ae2006466a0, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Wed Feb 26 00:15:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653852, encodeId=387e1653852e9, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Sun Jun 28 07:15:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046173, encodeId=455720461e3b4, content=<a href='/topic/show?id=4dbb4003e19' target=_blank style='color:#2F92EE;'>#唾液皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40037, encryptionId=4dbb4003e19, topicName=唾液皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 31 03:15:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914468, encodeId=4a1a1914468b8, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Dec 28 22:15:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011416, encodeId=97132011416b0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Jul 22 13:15:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275189, encodeId=1fff12e51895f, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277820, encodeId=efc712e7820ae, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445299, encodeId=01021445299f9, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=)]
    2019-10-02 linlin2312
  9. [GetPortalCommentsPageByObjectIdResponse(id=2044111, encodeId=fdc82044111d2, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 12 16:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774855, encodeId=69f01e74855fd, content=<a href='/topic/show?id=fb905115046' target=_blank style='color:#2F92EE;'>#心理应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51150, encryptionId=fb905115046, topicName=心理应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bf538680838, createdName=nian.wang1995, createdTime=Wed Jun 10 17:15:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006466, encodeId=93ae2006466a0, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Wed Feb 26 00:15:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653852, encodeId=387e1653852e9, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Sun Jun 28 07:15:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046173, encodeId=455720461e3b4, content=<a href='/topic/show?id=4dbb4003e19' target=_blank style='color:#2F92EE;'>#唾液皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40037, encryptionId=4dbb4003e19, topicName=唾液皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 31 03:15:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914468, encodeId=4a1a1914468b8, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Dec 28 22:15:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011416, encodeId=97132011416b0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Jul 22 13:15:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275189, encodeId=1fff12e51895f, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277820, encodeId=efc712e7820ae, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445299, encodeId=01021445299f9, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2044111, encodeId=fdc82044111d2, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 12 16:15:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774855, encodeId=69f01e74855fd, content=<a href='/topic/show?id=fb905115046' target=_blank style='color:#2F92EE;'>#心理应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51150, encryptionId=fb905115046, topicName=心理应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bf538680838, createdName=nian.wang1995, createdTime=Wed Jun 10 17:15:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006466, encodeId=93ae2006466a0, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Wed Feb 26 00:15:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653852, encodeId=387e1653852e9, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Sun Jun 28 07:15:00 CST 2020, time=2020-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046173, encodeId=455720461e3b4, content=<a href='/topic/show?id=4dbb4003e19' target=_blank style='color:#2F92EE;'>#唾液皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40037, encryptionId=4dbb4003e19, topicName=唾液皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 31 03:15:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914468, encodeId=4a1a1914468b8, content=<a href='/topic/show?id=103f3264681' target=_blank style='color:#2F92EE;'>#前瞻性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32646, encryptionId=103f3264681, topicName=前瞻性研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Dec 28 22:15:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011416, encodeId=97132011416b0, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Jul 22 13:15:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275189, encodeId=1fff12e51895f, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277820, encodeId=efc712e7820ae, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445299, encodeId=01021445299f9, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Wed Oct 02 13:15:00 CST 2019, time=2019-10-02, status=1, ipAttribution=)]

相关资讯

Neurology:无痴呆老年人唾液皮质醇与脑体积以及认知功能之间的关系

目的:调查无痴呆老年人早晚唾液皮质醇水平与脑体积以及认知功能的关系。方法:在雷克雅维克的AGES研究中,选取4244无痴呆,年龄在76± 5 岁的老年人,女性占58%。对所有研究对象进行1.5T脑MRI扫描,评估其认知功能,以及在家收集醒后、睡前45分钟的唾液。校正协变量后,应用直线回归分析皮质醇,脑体积以及认知功能的关系。结果:晚间皮质醇水平升高与脑体积(最高水平 vs 最低水平 -16.0 m